These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6388363)

  • 21. Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder.
    Skodol AE; Gunderson JG; McGlashan TH; Dyck IR; Stout RL; Bender DS; Grilo CM; Shea MT; Zanarini MC; Morey LC; Sanislow CA; Oldham JM
    Am J Psychiatry; 2002 Feb; 159(2):276-83. PubMed ID: 11823271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of thiothixene with chlorpromazine in the treatment of mania.
    Janicak PG; Bresnahan DB; Sharma R; Davis JM; Comaty JE; Malinick C
    J Clin Psychopharmacol; 1988 Feb; 8(1):33-7. PubMed ID: 3280617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoxetine in the treatment of borderline and schizotypal personality disorders.
    Markovitz PJ; Calabrese JR; Schulz SC; Meltzer HY
    Am J Psychiatry; 1991 Aug; 148(8):1064-7. PubMed ID: 1853957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Schizotypal symptoms in patients with borderline personality disorders.
    George A; Soloff PH
    Am J Psychiatry; 1986 Feb; 143(2):212-5. PubMed ID: 3946657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of phenothiazine and nonphenothiazine neuroleptics according to psychopathology, side effects and computerized EEG.
    Itil TM; Patterson CD; Keskiner A; Holden JM
    Adv Biochem Psychopharmacol; 1974; 9(0):499-509. PubMed ID: 4599437
    [No Abstract]   [Full Text] [Related]  

  • 26. The significance of borderline and schizotypal overlap.
    Plakun EM; Muller JP; Burkhardt PE
    Hillside J Clin Psychiatry; 1987; 9(1):47-54. PubMed ID: 3653842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug treatment of the personality disorders.
    Stein G
    Br J Psychiatry; 1992 Aug; 161():167-84. PubMed ID: 1355689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 14-year follow-up of borderline and schizotypal personality disorders.
    Plakun EM; Burkhardt PE; Muller JP
    Compr Psychiatry; 1985; 26(5):448-55. PubMed ID: 4028695
    [No Abstract]   [Full Text] [Related]  

  • 29. The amphetamine challenge test in patients with borderline disorder.
    Schulz SC; Cornelius J; Schulz PM; Soloff PH
    Am J Psychiatry; 1988 Jul; 145(7):809-14. PubMed ID: 3381923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of melancholia during carbamazepine treatment in borderline personality disorder.
    Gardner DL; Cowdry RW
    J Clin Psychopharmacol; 1986 Aug; 6(4):236-9. PubMed ID: 3525615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Speed and rate of remission in acute schizophrenia: a comparison of intramuscularly administered fluphenazine HC1 with thiothixene and haloperidol.
    Levenson AJ; Burnett GB; Nottingham JD; Sermas CE; Thornby JI
    Curr Ther Res Clin Exp; 1976 Nov; 20(5):695-700. PubMed ID: 825356
    [No Abstract]   [Full Text] [Related]  

  • 32. Heterogeneity of schizophrenia: relationship to latency of neuroleptic response.
    McDermott BE; Sautter FJ; Garver DL
    Psychiatry Res; 1991 Apr; 37(1):97-103. PubMed ID: 1862165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment utilization by patients with personality disorders.
    Bender DS; Dolan RT; Skodol AE; Sanislow CA; Dyck IR; McGlashan TH; Shea MT; Zanarini MC; Oldham JM; Gunderson JG
    Am J Psychiatry; 2001 Feb; 158(2):295-302. PubMed ID: 11156814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of efficacy of zotepine and thiothixene in schizophrenia in a double-blind study.
    Sarai K; Okada M
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):38-46. PubMed ID: 2883680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Borderline personality disorder: symptomatology and MMPI characteristics.
    Resnick RJ; Schulz P; Schulz SC; Hamer RM; Friedel RO; Goldberg SC
    J Clin Psychiatry; 1983 Aug; 44(8):289-92. PubMed ID: 6874649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder.
    Hollander E; Swann AC; Coccaro EF; Jiang P; Smith TB
    Am J Psychiatry; 2005 Mar; 162(3):621-4. PubMed ID: 15741486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alprazolam-induced dyscontrol in borderline personality disorder.
    Gardner DL; Cowdry RW
    Am J Psychiatry; 1985 Jan; 142(1):98-100. PubMed ID: 2857071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive and perceptual distortions in borderline personality disorder and schizotypal personality disorder in a vignette sample.
    Sternbach SE; Judd PH; Sabo AN; McGlashan T; Gunderson JG
    Compr Psychiatry; 1992; 33(3):186-9. PubMed ID: 1591910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial transmission of schizotypal and borderline personality disorders.
    Baron M; Gruen R; Asnis L; Lord S
    Am J Psychiatry; 1985 Aug; 142(8):927-34. PubMed ID: 4025588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double blind comparison of thiothixene and a trifluoperazine/chlorpromazine composite in the treatment of chronic schizophrenia.
    Knight RG; Harrison A
    N Z Med J; 1979 Apr; 89(634):302-4. PubMed ID: 377155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.